Standardized TREM Production via Affinity Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing purified tRNA effector molecules (TREMs) are inefficient and lack standardization, leading to variations in purity, activity, and stability, which affects their therapeutic applications.
Innovation Solution
A method involving the use of mammalian host cells expressing exogenous nucleic acids encoding TREMs, followed by purification and formulation with pharmaceutical excipients to create a standardized, GMP-grade REM composition, ensuring high purity and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for producing purified tRNA effector molecules are used, then production can be achieved, but the efficiency is low and standardization is lacking, leading to variations in purity, activity, and stability
Solution Approach 1:
The patent applies parameter changes by optimizing specific conditions for tRNA expression and purification, including controlling RNA polymerase III promoter strength, adjusting purification buffer compositions, and standardizing incubation temperatures and times. These parameter optimizations enable both high-yield production and consistent purity levels across batches.
Solution Approach 2:
The patent replaces traditional mechanical purification methods with affinity-based purification systems using tagged tRNA molecules. This substitution enables automated, standardized purification processes that maintain consistent purity levels while improving overall production efficiency and reducing manual intervention.
2Manufacturing precision
If traditional purification methods are used, then some purification can be achieved, but the purity and activity levels are insufficient for pharmaceutical use
Solution Approach 1:
The patent introduces affinity tags as intermediary elements that temporarily attach to tRNA molecules during purification. These tags serve as mediators between the tRNA and purification matrices, enabling high-purity isolation through specific binding interactions. The tags are subsequently removed to yield pure, active tRNA suitable for pharmaceutical applications.
Solution Approach 2:
The purification process is segmented into distinct modular steps: initial crude purification, affinity-based intermediate purification, and final polishing steps. Each segment targets specific impurity types and can be independently optimized, making the overall process both highly effective and manageable despite its complexity.
3Manufacturing precision
If multiple purification steps are implemented to increase purity, then purity improves, but the production time and complexity increase
Solution Approach 1:
The patent merges multiple purification functions into integrated affinity purification modules that simultaneously achieve concentration, purification, and quality control in single操作步骤. This consolidation maintains high purity levels while reducing the number of separate processing steps and overall production time.
Solution Approach 2:
The patent performs preliminary purification actions during the expression phase by designing expression systems that co-produce purification tags and structural components. This preliminary preparation reduces the burden on subsequent purification steps, enabling faster processing while maintaining consistent purity levels across batches.
Data Source
AI summary
The invention relates generally to tRNA-based effector molecules and methods relating thereto.